Sorafenib and everolimus in advanced clear cell renal carcinoma: A phase I/II trial of the SCRI oncology research consortium

Cancer Investigation

Volumn 31, Issue 5, 2013, Pages 323-329

  Hainsworth, John D ^a,b   Waterhouse, David M ^a,c   Penley, William C ^a,b   Shipley, Dianna L ^a,b   Thompson, Dana S ^a,b   Webb, Charles D ^d   Anthony Greco, F ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Oncology Hematology Care Inc   (United States)

^d Baptist Hospital East   (United States)

Author keywords

Angiogenesis; Clinical trials; Kidney; Ureter; Urethra Penis Cancer

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; GAMMA INTERFERON; INTERLEUKIN 2; SORAFENIB; SUNITINIB;

ACUTE KIDNEY FAILURE; ADRENAL METASTASIS; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DYSPNEA; FATIGUE; FEASIBILITY STUDY; FEMALE; HAND FOOT SYNDROME; HEART INFARCTION; HEPATITIS B; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEPHRECTOMY; ORAL MUCOSITIS; OVERALL SURVIVAL; PANCREAS METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SEPSIS; SINUSITIS; SKIN TOXICITY; STOMATITIS; THYROID METASTASIS; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HAND-FOOT SYNDROME; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; SIROLIMUS; TREATMENT OUTCOME;

EID: 84877946281     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2013.789900     Document Type: Article

References (16)

1. Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V. Phase III trial of be-vacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): fnal analysis of overall survival. J Clin Oncol 2010;28:2144-2150.0
2. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134. (Pubitemid 46089673)
3. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281. (Pubitemid 46849157)
4. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, By-cott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124. (Pubitemid 46089672)
5. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Brac-arda S, Grunwald V, Tompson JA, Figlin RA, Hollaender N, Ur-banowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. Efcacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-456.
6. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaf J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-1068.
7. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative efective-ness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-1939.
8. Terasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
10. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-463. (Pubitemid 41079774)
11. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefts of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-1295. (Pubitemid 36554699)
12. Land SC, Tee AR. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 2007;282:20534-20543. (Pubitemid 47100043)
13. O'Donnell A, Faivre S, Burris HA, 3rd, Rea D, Papadimi-trakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I. Phase I pharmacoki-netic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26:1588-1595.
14. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, Fischer P, Ronnen E, Ishill N, Patil S, Motzer RJ. Phase I trial of bevacizumab plus escalated doses of suni-tinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1432-1439.
15. Escudier BJ, Negrier S, Gravis G, Chevreau C, Delva R, Bay J, Geofrois L, Legoufe E, Blanc E, Ferlay C. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. ASCO Meeting Abstracts 2010;28:4516.
16. Hainsworth JD, Spigel DR, Burris HA, 3rd, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010;28:2131-2136.